BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia
CAMBRIDGE, Mass. and BEIJING, China, Dec. 16, 2019 (GLOBE NEWSWIRE) — BeiGene Co.,Ltd, (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing...

